Akebia Therapeutics to Participate in Upcoming Investor Conferences
Aug. 30, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug 30, 2018--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participate in the following investor conferences:
A live webcast of the presentations will be available on the company’s website at www.akebia.com. To access, please log onto the Akebia website at least 15 minutes prior to the webcasts to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Akebia’s website following the conferences.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180830005583/en/
CONTACT: Akebia Therapeutics
John Garabo, 617-844-6130
Director, Corporate Communications
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL GENERAL HEALTH
SOURCE: Akebia Therapeutics, Inc.
Copyright Business Wire 2018.
PUB: 08/30/2018 04:05 PM/DISC: 08/30/2018 04:05 PM